Avastin doesn't blind people, people blind people

摘要

WE READ WITH GREAT INTEREST THE PERSPECTIVE BY GON-zalez and associates regarding how to compound bevaci-zumab safely to minimize the risks of contamination.1 The article, however, overlooks a fact that seems to be lost in the bevacizumab versus ranibizumab debate: using a medication that is approved by the Food and Drug Administration (FDA) for intraocular injection avoids the need to expose patients to the added risk of a compounded, off-label agent like bevacizumab.